260 related articles for article (PubMed ID: 28270509)
21. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.
Ghiotto M; Gauthier L; Serriari N; Pastor S; Truneh A; Nunès JA; Olive D
Int Immunol; 2010 Aug; 22(8):651-60. PubMed ID: 20587542
[TBL] [Abstract][Full Text] [Related]
22. Tissue expression of PD-L1 mediates peripheral T cell tolerance.
Keir ME; Liang SC; Guleria I; Latchman YE; Qipo A; Albacker LA; Koulmanda M; Freeman GJ; Sayegh MH; Sharpe AH
J Exp Med; 2006 Apr; 203(4):883-95. PubMed ID: 16606670
[TBL] [Abstract][Full Text] [Related]
23. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
Fife BT; Pauken KE; Eagar TN; Obu T; Wu J; Tang Q; Azuma M; Krummel MF; Bluestone JA
Nat Immunol; 2009 Nov; 10(11):1185-92. PubMed ID: 19783989
[TBL] [Abstract][Full Text] [Related]
24. Partial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/ PD-L1 pathway.
Lages CS; Lewkowich I; Sproles A; Wills-Karp M; Chougnet C
Aging Cell; 2010 Oct; 9(5):785-98. PubMed ID: 20653631
[TBL] [Abstract][Full Text] [Related]
25. Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex.
Garrett-Thomson SC; Massimi A; Fedorov EV; Bonanno JB; Scandiuzzi L; Hillerich B; Seidel RD; Love JD; Garforth SJ; Guha C; Almo SC
PLoS One; 2020; 15(6):e0233578. PubMed ID: 32497097
[TBL] [Abstract][Full Text] [Related]
26. High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2.
Li Y; Liang Z; Tian Y; Cai W; Weng Z; Chen L; Zhang H; Bao Y; Zheng H; Zeng S; Bei C; Li Y
Cancer Sci; 2018 Aug; 109(8):2435-2445. PubMed ID: 29890018
[TBL] [Abstract][Full Text] [Related]
27. Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro.
Kim JH; Kim YS; Choi JG; Li W; Lee EJ; Park JW; Song J; Chung HS
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375257
[TBL] [Abstract][Full Text] [Related]
28. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.
Bennett F; Luxenberg D; Ling V; Wang IM; Marquette K; Lowe D; Khan N; Veldman G; Jacobs KA; Valge-Archer VE; Collins M; Carreno BM
J Immunol; 2003 Jan; 170(2):711-8. PubMed ID: 12517932
[TBL] [Abstract][Full Text] [Related]
29. Human naive and memory T-helper cells display distinct adhesion properties to ICAM-1, LFA-3 and B7 molecules.
Parra E; Wingren AG; Hedlund G; Sjögren HO; Kalland T; Sansom D; Dohlsten M
Scand J Immunol; 1993 Dec; 38(6):508-14. PubMed ID: 7504826
[TBL] [Abstract][Full Text] [Related]
30. In Vitro Assays to Study PD-1 Biology in Human T Cells.
Tocheva AS; Lerrer S; Mor A
Curr Protoc Immunol; 2020 Sep; 130(1):e103. PubMed ID: 32757378
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
Bodhankar S; Chen Y; Vandenbark AA; Murphy SJ; Offner H
J Neuroinflammation; 2013 Sep; 10():111. PubMed ID: 24015822
[TBL] [Abstract][Full Text] [Related]
32. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
33. Restriction of PD-1 function by
Sugiura D; Maruhashi T; Okazaki IM; Shimizu K; Maeda TK; Takemoto T; Okazaki T
Science; 2019 May; 364(6440):558-566. PubMed ID: 31000591
[TBL] [Abstract][Full Text] [Related]
34. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
Menke J; Lucas JA; Zeller GC; Keir ME; Huang XR; Tsuboi N; Mayadas TN; Lan HY; Sharpe AH; Kelley VR
J Immunol; 2007 Dec; 179(11):7466-77. PubMed ID: 18025191
[TBL] [Abstract][Full Text] [Related]
35. Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity.
Shrestha R; Garrett SC; Almo SC; Fiser A
Structure; 2019 May; 27(5):829-836.e3. PubMed ID: 30930066
[TBL] [Abstract][Full Text] [Related]
36. Programmed death ligand 2 regulates arginase induction and modifies Trypanosoma cruzi survival in macrophages during murine experimental infection.
Dulgerian LR; Garrido VV; Stempin CC; Cerbán FM
Immunology; 2011 May; 133(1):29-40. PubMed ID: 21303364
[TBL] [Abstract][Full Text] [Related]
37. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.
He YF; Zhang GM; Wang XH; Zhang H; Yuan Y; Li D; Feng ZH
J Immunol; 2004 Oct; 173(8):4919-28. PubMed ID: 15470033
[TBL] [Abstract][Full Text] [Related]
38. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Latchman Y; Wood CR; Chernova T; Chaudhary D; Borde M; Chernova I; Iwai Y; Long AJ; Brown JA; Nunes R; Greenfield EA; Bourque K; Boussiotis VA; Carter LL; Carreno BM; Malenkovich N; Nishimura H; Okazaki T; Honjo T; Sharpe AH; Freeman GJ
Nat Immunol; 2001 Mar; 2(3):261-8. PubMed ID: 11224527
[TBL] [Abstract][Full Text] [Related]
39. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
40. PD-1 and its ligands in tolerance and immunity.
Keir ME; Butte MJ; Freeman GJ; Sharpe AH
Annu Rev Immunol; 2008; 26():677-704. PubMed ID: 18173375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]